# Trial of Surufatinib Combined With JS001 in the Treatment of Advanced Solid Tumors

> **NCT03879057** · PHASE1 · UNKNOWN · sponsor: **Peking University** · enrollment: 24 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Surufatinib/humanized anti-PD-1 monoclonal antibody

## Key facts

- **NCT ID:** NCT03879057
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-21
- **Primary completion:** 2020-12-20
- **Final completion:** 2021-12-20
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2019-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03879057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03879057, "Trial of Surufatinib Combined With JS001 in the Treatment of Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03879057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*